Abstract library

130 results for "tool".
#2893 Prediction of Survival for Gastrointestinal Neuroendocrine Tumors: A Systematic Review of Clinical Tools
Introduction: Clinical prediction tools aggregate patient and disease information to predict outcomes. Little is known about gastrointestinal neuroendocrine tumors (GI-NET) prediction tools accuracy and utility.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Julie Hallet
Authors: Hallet J, Ho G, Beyfuss K, Chan D, ...
#2277 Neuroendocrine Tumors Committee of Reference Hospital: Decision-Making Process on the Diagnostic and Therapeutic Approach to Patients with Neuroendocrine Tumors
Introduction: Neuroendocrine tumors (NETs) require a multidisciplinary approach in expert centers due to their rarity, heterogeneity and the lack of evidence about optimal clinical management.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: PhD Paula Jimenez-Fonseca
#2751 Cross-Sectional Study Assessing the Feasibility of Using NET VITALS Communication Tool among Patients with Neuroendocrine Tumors
Introduction: Neuroendocrine tumor (NET) patients have reported ineffective communication with medical providers as a barrier to quality care.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Daneng Li
Authors: Li D, Imbesi G, Yen L, Kim H, ...
#2863 Introduction of Dosimetry on PRRT Practice. A Useful Tool to Detect Responders and Evaluate Treatment Safety
Introduction: PRRT is a recognized salvage option for G1-G2 GEPNET. Currently, the Italian protocol (Lutathera AIFA Guidelines) consists in four fixed-dose of 177 Lu-DOTATATE. The dosimetry has recently been recognized as an important tool to guide PRRT but is not yet part of routine practice.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: MD Federica Scalorbi
#290 Peptide Receptor Radiotherapy as a Potential Tool of Neoadjuvant Therapy in Patients with Inoperable Neuroendocrine Tumors (NETs)
Introduction: Neoadjuvant treatment is used as pre-surgical therapy in different cancers to decrease tumor size. PRRT can be a useful tool in neoadjuvant treatment of patients with well-differentiated NETs.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Anna Sowa-Staszczak
#541 Contrast-Enhanced Ultrasound (CEUS) is a Helpful Tool to Predict the Effectiveness of Somatostatin Analogues in Patients with Liver Metastases From Neuroendocrine Tumors
Introduction: Contrast-enhanced ultrasonography (CEUS) allows characterization of the micro-vascularization of tumor lesions. Liver metastases (LM) from neuroendocrine tumors (NET) show a typical pattern on CEUS, consistent with a rapid, intense and homogeneous enhancement (hypervascular pattern) in the arterial phase.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Valeria Ramundo
#813 Comparison of Manual and Automatic Methods of Ki-67 Proliferation Index for Neuroendocrine Tumors: The Development and Validation of a Novel Digital Pathology Tool (Ki-67Counter)
Introduction: Ki-67 proliferation index is an increasingly important biomarker used to grade neuroendocrine tumors. Manual counting methods are laborious and subject to inter- and intra-observer variability. Digital counting methods hold promise for fast and reproducible indices, however, they are fraught with technical difficulties.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: Dr. Lin Yang
Authors: Neltner J, Su H, Xing F, Rosser J, ...
#857 Video Capsule Endoscopy as a Tool to Detect Small Bowel Neuroendocrine Tumors
Introduction: Recent studies suggest that video capsule endoscopy (CE) should be implemented in diagnostic work-up in patients with suspected small bowel tumors. Small bowel is the primary site in 80%-85% of patients with intestinal neuroendocrine tumors (NET). In 10%-15% of patients diagnosed with metastasized NET, the localization of the primary tumors remains obscure.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Helen Miller
#589 Pancreatic neuroendocrine tumors and Diffusion weighted MRI: a better tool for detection?
Introduction: Pancreatic neuroendocrine tumors (pNETs) are often difficult to detect because of small size. Because surgery is curative in localized pNETs, preoperative localization is necessary.
Conference:
Category: Clinical
Presenting Author: Miss Alessandra Farchione
#861 Targeted Next Generation Sequencing in the Screening for Familial Neuroendocrine Tumor Syndromes: A Tool for Personalized Medicine
Introduction: Multiple syndromes are described as conferring susceptibility to NETs; MEN1 & 2, NF1, familial PGL 1-5, TSC, VHL and germline mutations in the HIF2A, MAX, or TMEM127. Genetic testing covering these diagnoses may be extensively resource-demanding using traditional techniques due to the large extent of these loci.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Biomarkers
Presenting Author: Joakim Crona